• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients

tetano

Editor, Senior Moderator
Sci Rep


. 2021 Aug 3;11(1):15701.
doi: 10.1038/s41598-021-95209-x.
Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients


Joram Huckriede[SUP] 1 [/SUP], Sara Bülow Anderberg[SUP] 2 [/SUP], Albert Morales[SUP] 3 [/SUP], Femke de Vries[SUP] 1 [/SUP], Michael Hultström[SUP] 2 4 [/SUP], Anders Bergqvist[SUP] 5 [/SUP], José T Ortiz-Pérez[SUP] 6 [/SUP], Jan Willem Sels[SUP] 7 8 [/SUP], Kanin Wichapong[SUP] 1 [/SUP], Miklos Lipcsey[SUP] 2 9 [/SUP], Marcel van de Poll[SUP] 7 10 [/SUP], Anders Larsson[SUP] 11 [/SUP], Tomas Luther[SUP] 2 [/SUP], Chris Reutelingsperger[SUP] 1 [/SUP], Pablo Garcia de Frutos[SUP] 12 [/SUP], Robert Frithiof[SUP] #[/SUP][SUP] 2 [/SUP], Gerry A F Nicolaes[SUP] #[/SUP][SUP] 13 [/SUP]



Affiliations

Abstract

Coronavirus disease 19 (COVID-19) presents with disease severities of varying degree. In its most severe form, infection may lead to respiratory failure and multi-organ dysfunction. Here we study the levels and evolution of the damage associated molecular patterns (DAMPS) cell free DNA (cfDNA), extracellular histone H3 (H3) and neutrophil elastase (NE), and the immune modulators GAS6 and AXL in relation to clinical parameters, ICU scoring systems and mortality in patients (n = 100) with severe COVID-19. cfDNA, H3, NE, GAS6 and AXL were increased in COVID-19 patients compared to controls. These measures associated with occurrence of clinical events and intensive care unit acquired weakness (ICUAW). cfDNA and GAS6 decreased in time in patients surviving to 30 days post ICU admission. A decrease of 27.2 ng/mL cfDNA during ICU stay associated with patient survival, whereas levels of GAS6 decreasing more than 4.0 ng/mL associated with survival. The presence of H3 in plasma was a common feature of COVID-19 patients, detected in 38% of the patients at ICU admission. NETosis markers cfDNA, H3 and NE correlated well with parameters of tissue damage and neutrophil counts. Furthermore, cfDNA correlated with lowest p/f ratio and a lowering in cfDNA was observed in patients with ventilator-free days.
 
Back
Top Bottom